Sexually transmitted disease (STD)
Also known as: Venereal disease, Genitals, Venereal, Genitalis, Genitalia
Methodology & AI Transparency ⓘ
Sexually transmitted disease (STD) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Bacterial, Viral & Fungal Infections practice, Sexually transmitted disease (STD) (also termed Venereal disease or Genitals) (ICD-10 A64) is stratified through antimicrobial stewardship (narrow-spectrum in Sexually transmitted disease (STD) (A64: pathogen-directed duration) or), pairing targeted symptom control with longitudinal Complete Blood Count in Sexually transmitted disease (STD) (A64: (WBC & Differential)) surveillance.
- 2 Real-world patient consensus: Synonyms for Sexually transmitted disease (STD) (A64): Venereal disease, Genitals, Venereal (Infections & Antivirals).
- 3 Typical cash cost range: Differential triage of Sexually transmitted disease (STD) (A64) utilizes antimicrobial stewardship (narrow-spectrum in Sexually transmitted disease (STD) (A64: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Objective lab/clinical target for Sexually transmitted disease (STD): Targeted PCR / in Sexually transmitted disease (STD) (A64: Culture & Sensitivity) (Pathogen clearance / negative test (A64)) and Complete Blood Count in Sexually transmitted disease (STD) (A64: (WBC & Differential)).
Ask our AI Specialists anything about Sexually transmitted disease (STD)
What Is Sexually transmitted disease (STD)?
Within Bacterial, Viral & Fungal Infections practice, Sexually transmitted disease (STD) (also termed Venereal disease or Genitals) (ICD-10 A64) is stratified through antimicrobial stewardship (narrow-spectrum in Sexually transmitted disease (STD) (A64: pathogen-directed duration) or), pairing targeted symptom control with longitudinal Complete Blood Count in Sexually transmitted disease (STD) (A64: (WBC & Differential)) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Sexually transmitted disease (STD) (ICD-10 A64) is driven by microbial (bacterial [Sexually transmitted disease (STD) A64]; specialists in Bacterial, Viral & Fungal Infections monitor Complete Blood Count in Sexually transmitted disease (STD) (A64: (WBC & Differential)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Sexually transmitted disease (STD) (A64): acute fever, chills, in Sexually transmitted disease (STD) (A64: malaise, and myalgias)
- • Secondary Sexually transmitted disease (STD) clinical sign: sore throat, productive in Sexually transmitted disease (STD) (A64: cough, sinus/ear pain,)
- • Symptom flares in Sexually transmitted disease (STD) correlating with Targeted PCR / in Sexually transmitted disease (STD) (A64: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (A64)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Sexually transmitted disease (STD) (A64: pathogen-directed duration) or) evaluation (A64)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sexually transmitted disease (STD) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A64 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Sexually transmitted disease (STD) (A64: Culture & Sensitivity) | Pathogen clearance / negative test (A64) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Sexually transmitted disease (STD) (A64: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A64) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Sexually transmitted disease (STD) (A64: Procalcitonin) | Resolution to baseline (A64) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sexually transmitted disease (STD)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nitrofurantoin Monohydrate/Macrocrystal Macrodantin • RxCUI 311994 | Nitrofuran Antibacterial | 87% | $2.5317 | $ 6.98 /mo |
| Cabotegravir Apretude • RxCUI 2588077 | FDA Prescription Therapeutic Agent | 74% | $1.9200 | $ 86.26 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sexually transmitted disease (STD))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Tadalafil on lower urinary tract symptoms secondary to benign prostatic: What a 505-Participant Study Found Tadalafil was efficacious and well tolerated in treating ED and LUTS/BPH in sexually active men with both conditions. The journal of sexual medicine • 2013-08-15 • Randomized Controlled Trial | N = 505 | 93/100 | PMID 23782459 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a Data from this large trial suggest that ARCT-154 is safe and well tolerated. Expert review of vaccines • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40195167 ↗ |
| Can This Approach Help? Inside the Latest Research on Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in In a Bayesian reanalysis of the PINETREE trial, there was a 98.9% or greater probability that treatment with RDV reduced the risk of COVID-19-related hospitalization or all-cause death across all prior probability distributions. PloS one • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41990093 ↗ |
Sexually transmitted disease (STD) Patient Community & “People Like Me” Threads
Filter Sexually transmitted disease (STD) community threads and patient logs by age, biological sex, dosage, and treatment duration.